TP53 and acute myeloid leukemia: Biologically, pediatric AML exhibits distinct driver mutation profiles (e.g., fewer TP53 mutations, more KMT2A rearrangements) (Bolouri et al., 2018) and epigenetic landscapes (Xu et al., 2022) that alter the clinical impact of shared pathway activations.